TEMGESIC Sublingual tablet Ref.[27661] Active ingredients: Buprenorphine

Source: Medicines & Healthcare Products Regulatory Agency (GB)  Revision Year: 2020  Publisher: Indivior UK Limited, The Chapleo Building, Henry Boot Way, Priory Park, Hull, HU4 7DY, United Kingdom

4.1. Therapeutic indications

As a strong analgesic for the relief of moderate to severe pain.

4.2. Posology and method of administration

Prior to starting treatment with opioids, a discussion should be held with patients to put in place a strategy for ending treatment with buprenorphine in order to minimise the risk of addiction and drug withdrawal syndrome (see section 4.4).

Posology

Adults and children over 12

200-400 micrograms to be dissolved under the tongue every 6-8 hours or as required. The recommended starting dose for moderate to severe pain of the type typically presenting in general practice is 200 to 400 micrograms, 8 hourly.

Elderly

There is no evidence that dosage needs to be modified for the elderly.

Children under 12 years

Temgesic Sublingual is suitable for use in children under 12 as follows:

16-25 kg (35-55 lb): 100 micrograms.

25-37.5 kg (55-82.5 lb): 100-200 micrograms.

37.5-50 kg (82.5-110 lb): 200-300 micrograms.

The recommended dose should be administered every 6-8 hours.

Sublingual administration is not suitable for children under the age of six years.

Temgesic sublingual may be used in balanced anaesthetic techniques at a dose of 400 micrograms.

Special populations

Patients with hepatic insufficiency

Buprenorphine is metabolised in the liver. The degree and duration of its action may be different in patients with hepatic impairment. Therefore, the Temgesic dose should be reduced for these patients accordingly (see section 4.4 and 5.2).

Method of administration

Administration by the sublingual route.

The tablet should not be chewed or swallowed whole as this will reduce efficacy.

4.9. Overdose

Patients should be informed of the signs and symptoms of overdose and to ensure that family and friends are also aware of these signs and to seek immediate medical help if they occur.

The expected symptoms of overdose would be drowsiness, nausea and vomiting; marked miosis may occur.

Supportive measures should be instituted and if appropriate Naloxone or respiratory stimulants can be used.

6.3. Shelf life

3 years – Nylon/aluminium/uPVC blister strip.

3 years – HDPE bottle.

6.4. Special precautions for storage

Do not store above 30°C. Store in the original package- Nylon/aluminium/uPVC blister strip

Do not store above 30°C – HDPE bottle.

6.5. Nature and contents of container

Nylon/aluminium/uPVC blister strips of 10 tablets each, packed in cartons of 50 tablets.

HDPE bottle consisting of 50 tablets.

6.6. Special precautions for disposal and other handling

To be dissolved under the tongue and not to be chewed or swallowed.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.